Benzinga | Jul 29, 2021 08:58AM EDT

Raymond James Maintains Outperform on Viking Therapeutics, Raises Price Target to $13

Raymond James analyst Steven Seedhouse maintains Viking Therapeutics (NASDAQ:VKTX) with a Outperform and raises the price target from $12 to $13.